We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Epidemiology and Risk Factors
-
1. Coronary heart disease epidemiology: global context for a new genetic understanding
- Prof. Harry Hemingway
-
2. Cardiovascular risk factors
- Dr. Michal Vrablik
-
3. Lipoproteins
- Prof. Arnold von Eckardstein
-
4. Thrombotic risk factors for cardiovascular disease
- Prof. Gordon Lowe
-
5. Lipoprotein(a)
- Dr. Jaimini Cegla
- Biology of Coronary Heart Disease
-
6. Plaque rupture
- Prof. Petri Kovanen
-
7. Transcription factors and complex disease development
- Dr. Ines Pineda-Torra
-
8. Animal models to explore cardiovascular disease
- Prof. Martin Merkel
- Treatment
-
9. Diagnosis and treatment of dyslipidemias
- Prof. Anton Stalenhoef
-
10. Key drug discovery challenges in cardiovascular medicine
- Dr. Dan Swerdlow
- Dr. Michael V. Holmes
- Genetics
-
11. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
12. Heart disease genes and SNPs
- Prof. Steve Humphries
-
13. Familial hypercholesterolaemia: genetic causes and treatment
- Prof. Steve Humphries
-
14. Familial hypercholesterolaemia: cascade testing and monogenic vs. polygenic causes
- Prof. Steve Humphries
-
16. Genetics of cardiovascular disease
- Prof. Philippa Talmud
-
17. The genetics of CHD: moving research findings into patient benefit
- Prof. Steve Humphries
-
19. The genetics of abdominal aortic aneurysm
- Dr. Seamus Harrison
-
20. Genome scans for hypertension
- Prof. Patricia Munroe
-
21. Telomeres and cardiovascular disease
- Dr. Jess Buxton
-
23. Genetics of hypertrophic cardiomyopathy (HCM)
- Dr. Petros Syrris
- Archived Lectures *These may not cover the latest advances in the field
-
24. Gene-environment interaction and oxidative stress in cardiovascular disease
- Dr. Jeffrey Stephens
-
25. Gene therapy as a therapeutic option for lipoprotein lipase deficiency
- Dr. Jan Albert Kuivenhoven
-
26. Cardiovascular diseases: from epidemiology to nutritional interventions
- Dr. Antonis Zampelas
-
27. Genetic testing for CHD risk: fact or fiction?
- Prof. Steve Humphries
-
28. Pharmacogenetics: progress, pitfalls and clinical potential
- Prof. Steve Humphries
-
29. Familial hyperchlolesterolaemia: a monogenic cause of early CHD
- Prof. Steve Humphries
-
30. Lipid metabolism
- Dr. Ulrike Beisiegel
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline: Lp(a) and CV risk
- Case study: Mrs K, age 57 (1)
- Mrs K: Lp(a) testing
- Lp(a) levels are genetically determined
- Elevated Lp(a) is a causal risk factor for CVD
- Lp(a) is a potent risk factor for MACE
- Lp(a) and graded risk
- Elevated Lp(a) is a risk factor for CV events across different ethnic groups
- Lp(a) pathophysiology
- Increased arterial wall inflammation and monocyte activation in patients with elevated Lp(a)
- Case study: Mrs K, age 57 (2)
- Mrs K.’s risk profile and managing her risk
- Talk outline: in whom to measure Lp(a)
- International guidelines
- In whom to measure Lp(a)
- Lp(a) and CAVS
- Talk outline: treatment
- Treatment options
- Aspirin
- Reducing residual risk
- PCSK9i
- Lipoprotein apheresis
- Lp(a) targeted therapies in development
- Antisense oligonucleotides
- Treatment
- Manage all risk factors for CVD
- Targets
- Talk outline: further research
- Future work
- Thanks for listening!
Topics Covered
- Lipoprotein(a)
- Lp(a) and cardiovascular (CV) risk
- Measuring Lp(a) levels
- Treatment for elevated Lp(a)
- Treating elevated Lp(a) using aspirin, lipoprotein apheresis, PCSK9i and antisense oligonucleotides
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Cegla, J. (2024, November 28). Lipoprotein(a) [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved March 14, 2025, from https://doi.org/10.69645/RYEJ3270.Export Citation (RIS)
Publication History
- Published on November 28, 2024
Financial Disclosures
- Speaker/consultancy fees or research grants from: Amgen, Sanofi, Amyrt, Pfizer, Novartis, Akcea, Silence Therapeutics, Verve Therapeutics, Ultragenyx.
A selection of talks on Biochemistry
Transcript
Please wait while the transcript is being prepared...
0:00
Hello there. My name
is Jaimini Cegla.
I'm a consultant in
Metabolic Medicine at
Imperial College
Healthcare NHS Trust.
I've got a special interest in
lipids and cardiovascular risk.
Today, I'm going to be talking
about lipoprotein(a),
or Lp(a) for short.
0:18
What I hope to cover over
the next 20 minutes or so
is the effect of lipoprotein(a)
concentration on cardiovascular risk,
in whom we should
consider measuring Lp(a),
some of the current and
future treatment options,
and further research avenues
that we have available.
0:37
I'm going to start
off with a case,
and this is someone that I'd
typically might see in my clinic.
This is Mrs. K.
She's a 57-year-old
lady and she's
got a background history
of some fibromyalgia,
and she had a PCI
to her LAD in 2022.
Her medicines are as
much as you would
expect in someone
who's had a PCI,
and she's on atorvastatin
20 milligrams
once a day for cholesterol.
There is a noise in
her family history.
Her father had an MI at 59
and her brother had a PCI at 62.
Her blood pressure is
pretty reasonable;
it could be slightly
more tightly controlled,
her BMI is 24 and
she's a non-smoker.
Looking at her lab tests,
we can see that
her CRP is normal;
her eGFR is normal.
She doesn't have diabetes,
and her lipids are not ideal;
her LDL cholesterol
probably could
be a bit more
tightly controlled.
1:31
That's the standard lipid
profile we would get.
However, in someone
like her who has not
really had any other
obvious risk factors
other than that family history,
in our clinic we would have
tested lipoprotein(a).
In this lady, her Lp(a)
came back at 355
nanomoles per liter.
To put this into context,
when we look at the EAS,
elevated Lp(a) thresholds,
you talk about 125
which equates to
the 83rd percentile of
Lp(a) concentration,
her levels are
exceptionally high.
These are between the 95th
and the 99th percentile.
These really help to
explain why this lady
may have had premature
cardiovascular disease.